Human Immunodeficiency Virus Type 1 immune-elicited antibodies and T cells (HIV-1 immune response)

Human Immunodeficiency Virus Type 1 (HIV-1) immune-elicited antibodies and T cells represent the collective adaptive immune response generated by the host to combat HIV-1 infection. This response includes humoral immunity, where B cells produce antibodies—specifically broadly neutralizing antibodies (bNAbs)—that target the HIV-1 envelope glycoprotein (Env) to prevent viral entry into host cells (Kwong & Mascola, 2018, Nature). Simultaneously, cellular immunity involves CD8+ cytotoxic T lymphocytes (CTLs) that recognize and eliminate infected cells by identifying viral peptides presented on MHC class I molecules, while CD4+ T cells provide essential helper functions (National Institute of Allergy and Infectious Diseases (NIAID), 2023). In therapeutic and prophylactic contexts, this 'target' refers to the goal of vaccines and immunotherapies to elicit or mimic these natural defenses to achieve viral control or prevention (Walker & McMichael, 2012, Nature Medicine). However, because this term describes a broad physiological process involving multiple cell types and proteins rather than a single molecular entity, it is considered a composite biological category rather than a discrete therapeutic target.

Other names

HIV-1 specific immune responseAnti-HIV-1 antibodies and T-cell immunityHIV-1 induced humoral and cellular immunityHost immune response to HIV-1

Induction or supplementation of the host immune system to recognize and neutralize HIV-1 virions (via antibodies) or destroy HIV-infected cells (via cytotoxic T cells).